Caption Management LLC Invests $670,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Caption Management LLC bought a new stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,371 shares of the company's stock, valued at approximately $670,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MLTX. FMR LLC boosted its position in MoonLake Immunotherapeutics by 28.1% during the fourth quarter. FMR LLC now owns 6,341,391 shares of the company's stock valued at $343,386,000 after purchasing an additional 1,391,167 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in MoonLake Immunotherapeutics by 12.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company's stock valued at $181,059,000 after purchasing an additional 363,394 shares during the last quarter. Federated Hermes Inc. raised its position in shares of MoonLake Immunotherapeutics by 13.2% in the fourth quarter. Federated Hermes Inc. now owns 1,280,052 shares of the company's stock valued at $69,315,000 after purchasing an additional 149,724 shares during the period. Marshall Wace LLP lifted its stake in shares of MoonLake Immunotherapeutics by 7.9% in the fourth quarter. Marshall Wace LLP now owns 1,245,299 shares of the company's stock worth $67,433,000 after buying an additional 90,914 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter worth $3,485,000. Institutional investors and hedge funds own 93.85% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on MLTX shares. HC Wainwright reissued a "buy" rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and set a $66.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Wednesday, April 30th. The Goldman Sachs Group lowered their target price on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Finally, Royal Bank of Canada began coverage on MoonLake Immunotherapeutics in a report on Tuesday, March 18th. They set an "outperform" rating and a $67.00 price target for the company. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $80.50.

MoonLake Immunotherapeutics Stock Down 6.3 %

Shares of MLTX opened at $39.26 on Wednesday. The stock's 50-day moving average price is $38.60 and its 200 day moving average price is $45.26. MoonLake Immunotherapeutics has a 12-month low of $31.42 and a 12-month high of $58.26. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -30.43 and a beta of 1.31.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09). Equities research analysts expect that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Want to see what other hedge funds are holding MLTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.